Cancer patients with COVID-19 who were treated with a drug combination promoted by U.S. President Donald Trump to counter the coronavirus were three times more likely to die within 30 days than those who got either drug alone, U.S. researchers reported.
Startup company ViralClear Pharmaceuticals’ broad-spectrum antiviral drug merimepodib is about to enter Phase II studies for COVID-19.
A hot, humid summer will slow coronavirus transmission but, on its own, is not likely to end the COVID-19 pandemic, according to a new study by researchers at the Massachusetts Institute of Technology, Harvard University, the University of Connecticut and Virginia Tech.
BioSpace reviews some recently published scientific studies, including researchers with the University of Colorado Anschutz Medical Campus releasing a new study calling attention to the emergence of mosquito-borne viral outbreaks in West Africa.
Oxford University and AstraZeneca are recruiting around 10,000 adults and children in Britain for trials of an experimental coronavirus vaccine, a day after receiving U.S. backing worth up to $1.2 billion.
Veeva Systems announced MyVeeva, a new application for clinical research sites.
The U.S. Centers for Disease Control and Prevention (CDC) plans a nationwide study of up to 325,000 people to track how the new coronavirus is spreading across the country into 2021 and beyond, a CDC spokeswoman and researchers conducting the effort told Reuters.
British researchers will study the genes of thousands of ill COVID-19 patients to try to crack one of the most puzzling riddles of the novel coronavirus: why does it kill some people but give others not even a mild headache?
Abbott Laboratories’ antibody test for the new coronavirus is highly likely to correctly determine whether people have ever been infected with the fast-spreading virus, the company said, citing a U.S. study.
A look at which parts of the body the novel coronavirus infects and how SARS-CoV-2 is transmitted from person to person.